

PUBLICATIONS BY THE HUNTINGTON STUDY GROUP

Articles

1. Huntington Study Group (Kiebertz K, primary author). The Unified Huntington's Disease Rating Scale: Reliability and Consistency. *Mov Dis* 1996;11:136-142.
2. Huntington Study Group (Marshall F, primary author). Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. *Neurol* 1998;50:1366-1373.
3. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kiebertz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I and the Huntington Study Group. Rate of functional decline in Huntington's disease. *Neurol* 2000;54:452-458.
4. The Huntington Study Group (Kiebertz K, primary author). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurol* 2001;57:397-404.
5. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, Huntington Study Group (Paulsen JS, primary author). Clinical markers of early disease in persons near onset of Huntington's disease. *Neurol* 2001;57:658-662.
6. Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme, Shoulson I and the Huntington Study Group. Predictors of nursing home placement in Huntington's disease. *Neurol* 2003;60:998-1001.
7. Mahant N, McCusker EA, Byth K, Graham S, The Huntington Study Group. Huntington's disease. Clinical correlates of disability and progression. *Neurol* 2003;61:1085-1092.
8. Huntington Study Group (Marshall F, primary author). Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. *Neurol* 2003; 61:1551-1556.
9. Peterson DR, Zhao H; Eapen S. Using local correlation in kernel-based smoothers for dependent data. *Biometrics* 2003; 59:984-991.
10. Nehl C, Paulsen JS and the Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. *J Nerv Ment Dis* 2004; 192:72-74.
11. Huntington Study Group (Cudkowicz M, primary author). Minocycline safety and tolerability in Huntington's disease. *Neurol* 2004;63:547-549.

12. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J, Huntington Study Group. Rate and correlates of weight change in Huntington's disease. *J Neurol Neurosurg Psych* 2004;75(2) 209-212.
13. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, and the Huntington Study Group. Interrater Agreement in the Assessment of Motor Manifestations of Huntington's Disease. *Mov Disord* 2005;20(3):293-297.
14. Quaid KA, Swenson M, Sims S, and the PHAROS Investigators and Coordinators. Qualitative interviews in a subset of PHAROS participants. *J Neurol Neurosurg Psych* 2005;76(suppl 4).
15. Huntington Study Group PHAROS Investigators (Quaid KA, primary author). Attitudes towards genetic testing for Huntington's disease in PHAROS participants. *J Neurol Neurosurg Psych* 2005;76(suppl 4).
16. Huntington Study Group PHAROS Investigators (Kayson EP, primary author). Monitoring the mental health and well being of the prospective Huntington at risk observational study (PHAROS) cohort. *J Neurol Neurosurg Psych* 2005;76(suppl 4).
17. Paulsen JS, Nehl C, Ferneyhough Hoth K, Benjamin M, Conybeare R, McDowell B, Turner B, The Huntington Study Group. Depression and Stages of Huntington's Disease. *J Neuropsychiatry Clin Neurosci* Fall 2005; 17:4:496-502.
18. Paulsen JS, Hoth K, Nehl C, Stierman L, The Huntington Study Group. Critical Periods of Suicide Risk in Huntington's Disease. *Am J Psychiatry* 2005;162:725-731.
19. Huntington Study Group, (Marshall F, primary author). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. *Neurology* 2006;66:366-372.
20. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E and the Predict-HD Investigators of the Huntington Study Group. Preparing for Preventive Clinical Trials: The Predict-HD Study. *Arch Neurol* 2006;63:883-890.
21. The Huntington Study Group PHAROS Investigators (Shoulson I, primary author). At Risk for Huntington Disease: The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. *Arch Neurol* 2006;63:991-998.
22. Marshall FJ, Fahn S, Clarence-Smith K (Reply from the authors). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. *Neurology* 2007;68:797.

23. Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, Oakes D, Shoulson I, Penziner E, Paulsen JS and the Predict-HD investigators of the Huntington's Study Group. Verbal episodic memory declines prior to diagnosis in Huntington's disease. *Neuropsychologia* 2007;45:1767-1776.
24. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. A study of chorea after tetrabenazine withdrawal in patients with Huntington's disease. *Clinical Neuropharmacology* (in press).
25. Langbehn DR, Paulsen JS, The Huntington Study Group. Predictors of diagnosis in Huntington disease. *Neurology* 2007;68:1710-1717.
26. Hersch S, Erwin C and the Event Monitoring Committee of the Huntington Study Group. Monitoring reportable events and unanticipated problems: the PHAROS and PREDICT studies of Huntington's disease. *IRB: Ethics & Human Research* 29(3):11-16,2007.
27. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K for the Huntington Study Group PHAROS Investigators. Fear of health insurance loss among individuals at risk for Huntington disease. *Am J Med Genet Part A* 2008;146A:2070-7.
28. Huntington Study Group TREND Investigators (Shoulson I, primary author). Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease: the TREND-HD Study. *Arch Neurol* 2008 Dec; 65(12): 1582-9.
29. Biglan K, Ross C, Langbehn D, Aylward E, Stout J, Queller S, Carlozzi N, Duff K, Beglinger L, Paulsen J and the PREDICT-HD Investigators of the Huntington Study Group. Motor Abnormalities in Premanifest Persons with Huntington's Disease: The PREDICT-HD Study. *Mov Dis* 2009; 24(12): 1763-72.
30. Frank S and the TETRA-HD Investigators of the Huntington Study Group. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. *BMC Neurology* 2009, 9:62 doi:10.1186/1471-2377-9-62.
31. Kieburtz K, McDermott M, Voss T, Corey-Bloom J, Deuel L, Dorsey ER, Factor S, Geschwind M, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A and The Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group. A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. *Arch Neurol*. 2010; 67(2): 154-160.

Acknowledgements to the Huntington Study Group

1. Peterson DR, Zhao H, Eapan S. Using local correlation in kernel-based smoothers for dependent data. *Biometrics* 2003;59:984-991.

Abstracts

1. Huntington Study Group (Como P, primary author). Internal validity and consistency of the Unified Huntington's Disease Rating Scale (UHDRS) (abstract), *Neurol* 45(Suppl 4) April 1995, p. A254.
2. Huntington Study Group (Marshall FJ, primary author). Inter-laboratory variability of (CAG)_n determinations in Huntington's disease (HD). *Neurol* 1996;46:A258.
3. Huntington Study Group (Paulsen JS, primary author). The clinical utility of the Stroop Test A in a multicenter study of Huntington's disease. *J Intl Neuropsychol Society* 1996;2:35.
4. Huntington Study Group (Bylsma FW, primary author). Noncognitive symptoms in Huntington's disease. *J Intl Neuropsychol Society* 1996;2:35.
5. Huntington Study Group (Como P, primary author). Neuropsychological assessment in multicenter clinical trials. *J Intl Neuropsychol Society* 1996;2:44.
6. Huntington Study Group (Marshall FJ, primary author). Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. *Mov Disord* 1996;11:59.
7. Marshall FJ, Taylor S and the Huntington Study Group. Aggression and irritability in Huntington disease: a survey of treatment patterns. *Neurol* 1997;48:A49.
8. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Twelfth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Etiology, Pathogenesis and Treatment of Huntington's Disease. *Mov Disord* 1998;13:858-863.
9. Hogarth P, Rosas D, Zhao H, Kayson E, Oakes D, Kieburtz K, Young AB, Wexler NS, Shoulson I and the Huntington Study Group. A study of inter-rater reliability of motor diagnosis of Huntington's disease. *Mov Disord* 1999;14:901.
10. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Thirteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 1999;14:898-909.
11. Volk M, Marshall M, McDermott M, Kieburtz K and the Huntington Study Group. Electrocardiographic manifestations of Huntington's disease. *Mov Disord* 1999;14:902.

12. Hogarth P and the Huntington Study Group. A study of the feasibility of clinical research in the Huntington's at-risk population. 18th International Meeting of the World Federation of Neurology Research Group on Huntington Disease, August 28-31, 1999, Program Abstracts: Huntington Disease/The Hague, The Netherlands, pp.105.
13. Wheelock V, Tempkin T, Marder K, Nance M, Myers R, Zhao H and the Huntington Study Group. Do Motor, Behavioral, or Psychiatric Correlates Predict the Need for Institutional Care in Patients with Huntington's Disease? *Ann Neurol* 2000;48:467.
14. Hogarth P and the Huntington Study Group. Gender disparity in study participation among individuals at risk for Huntington's disease. *Mov Disord* 2000;15:1042.
15. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Fourteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2000;15:1038-1048.
16. Huntington Study Group (K Kieburtz, presenter). Placebo-Controlled Trial of Creatine in Huntington's Disease. *Neurol* 2001;56:A386.
17. Peavy, Gm, Wilson L, Jacobsen MW, Hamilton JM, Jerkins SM, Corey-Bloom J, Psychiatric symptoms as a function of Huntington's disease diagnosis, *Neurol*, 2001;56(Suppl 3):A22.
18. Huntington Study Group (FJ Marshall, presenter). Riluzole dosing in Huntington's Disease (RID-HD): Results of an 8-week double-blind, placebo-controlled, multi-center study by the Huntington Study Group. *Proceedings of the 19th International Meeting of the World Federation of Neurology Research Group on Huntington's Disease*, August 25-28, 2001, Copenhagen, Denmark. Publication of the Panum Institute, p. 29-30, 2001.
19. Huntington Study Group (E Kayson, presenter). Preliminary report of the safety and feasibility of a controlled observational study of adults at risk for Huntington's disease (PHAROS). *Proceedings of the 19th International Meeting of the World Federation of Neurology Research Group on Huntington's Disease*, August 25-28, 2001, Copenhagen, Denmark. Publication of the Panum Institute, p. 30, 2001.
20. Huntington Study Group (MA Shinaman, presenter). Willingness to consent for future genetic testing by individuals at risk for or with Huntington's disease: A preliminary report. *Mov Disord* 2001;16:987.
21. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Fifteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2001;15:981-994.

22. Huntington Study Group (FJ Marshall, presenter). The frequency and severity of disruptive behavior and irritability in Huntington's disease. *Mov Disord* 2001;16:S45.
23. Huntington Study Group (JM Hamilton, presenter). Correlates of Weight Change in Huntington's Disease. *Neurol* 2002;58(Suppl 3):A309, abstract #P04.130.
24. Huntington Study Group (N Mahant, presenter). Huntington Disease: Does Mode of Onset Determine Disease Course. *Neurol* 2002;58 (Suppl 3):A333, abstract #S46.001.
25. Huntington Study Group (K Marder, presenter) Longitudinal Evaluation of Motor Signs in Huntington's Disease. *Neurol* 2002;58(Suppl 3):A333, abstract #S46.002.
26. Huntington Study Group (E Kayson, presenter) Safety and Feasibility of the Prospective Huntington at Risk Observational Study (PHAROS): A Preliminary Report. *Neurol* 2002;58(Suppl 3):A334-335, abstract #S46.005.
27. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Sixteenth Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2002;17:1103-1114.
28. Djousse L. Knowlton B. Cupples LA. Marder K. Shoulson I. Myers RH. Weight loss in early stage of Huntington's disease. *Neurol* 59:1325-30, 2002.
29. Huntington Study Group (M. Cudkowicz, primary author). Minocycline safety and tolerability in Huntington's disease. *Mov Disord* 2003;18:1084.
30. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Seventeenth Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2003;18:1082-1095.
31. Huntington Study Group/PHAROS Investigators (E. Kayson, primary author). Safety and feasibility of the Prospective Huntington At Risk Observational Study (PHAROS): A progress report. Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington's Disease, Abstract #70, page 70, 2003.

32. Huntington Study Group/PHAROS Investigators (K. Biglan, primary author). Emerging cohort characteristics in the Prospective Huntington At Risk Observation Study (PHAROS). Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington's Disease, Abstract #81, page 73, 2003.
33. Huntington Study Group/Predict-HD Investigators (J.S. Paulsen, primary author). Initial baseline characteristics in the Predict-HD (Neurobiological Predictors of HD) Study. Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington's Disease, Abstract #89, page 75, 2003.
34. Frank SA, Marshall F, Plumb S, Oakes D, Shoulson I, Kieburtz K, CARE-HD Investigators of the Huntington Study Group. Functional decline due to chorea in Huntington's disease. *Neurol* 2004;62(Suppl 5):A204.
35. Ross CA, Aylward EH, Stout JC, Biglan KM, Hayden MR, Shoulson I, Langbehn DR, Paulsen JS, The Predict-HD Investigators of the HSG. Clinical and radiographic features among presymptomatic individuals carrying an expanded CAG repeat in the Huntington's disease gene: Analysis of baseline characteristics of the PREDICT-HD Cohort. *Neurol* 2004;62(Suppl 5):A357.
36. Kayson EP, Huntington Study Group/PHAROS Investigators. The welfare of research participants in the Prospective Huntington At-Risk Observational Study (PHAROS). *Mov Disord* 2004;19(Suppl 9):S352.
37. Huntington Study Group (F.J. Marshall, presenter). A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine in Patients with Huntington's Disease. *Mov Disord* 2004;19:1122.
38. Kayson E, Darnell M, Weber J, Biglan K, Shoulson I, and the Huntington Study Group PHAROS Investigators. Depression and Suicidality at Baseline in the Prospective Huntington At Risk Observational Study (PHAROS). *Mov Disord* 2004;19:1128.
39. Ravina B, DiProspero N, Fagan SC, Fischbeck K, Harrison M, Hart R, Heemskerk J, Murphy D, Profenno L, Blumenstein R, Signer ER, Taylor JP, Tretheway JA, Hovinga CA. Systematic Evaluation of Treatments for Huntington's Disease (SET-HD): An Interim Report. Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).
40. Briner L, Bain L, Blumenstein R, Kieburtz K, Shinaman A, Shoulson I. The Huntington Project: Collaborative Huntington's Disease Clinical Research. Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).

41. Huntington Study Group PHAROS Investigators (Kayson EP, presenter). The Features and Well Being of the Prospective Huntington At Risk Observational Study (PHAROS) Cohort. Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).
42. Huntington Study Group (HSG) PHAROS Investigators (Shinaman A, presenter). Willingness to Consent for Future Use of Biological Specimens in the Prospective Huntington At Risk Observational Study (PHAROS). Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).
43. Shinaman MA, Gusella J, Foroud T, Gray J, Conneally M, Shoulson I, O'Donoghue K, Kayson E, Blumenstein R, Harrison M, Nance M, Suchowersky O, Tempkin T. Cooperative Huntington's Observational Research Trial (COHORT): An Initial Report. Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).
44. Elise Kayson, Elaine Julian-Baros, Christine Weaver, Aileen Shinaman, Connie Orme, Joseph Weber, Susan Daigneault, Anne B. Young, Ira Shoulson and the Huntington Study Group (HSG) PHAROS Investigators. Recruitment Strategies for the Prospective Huntington At Risk Observational Study (PHAROS). Published in the program booklet of Huntington Study Group 12th Annual Meeting 2004, Abstract # 8.
45. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Eighteenth Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2004;19:1118-1134.
46. Kevin M. Biglan and PHAROS Investigators. Baseline Characteristics of the Prospective Huntington at Risk Observational Study Cohort. *Annals Neuro* 2004;56(suppl 8):S24.
47. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, the US-Venezuela Huntington's Disease Collaborative Research Group; and the Huntington Study Group. Inter-Rater Agreement in the Assessment of the Motor Manifestations of Huntington's Disease. *Mov Disord* 2005;20:298-305.
48. Frank S, Ondo W, Hunter C, Marshall F, Walker F, Eberly S, Factor S, Fahn S, Hunt V, Oakes D, Plumb S, Shinaman A, Shoulson I, Zhao H, Jankovic J. A randomized, double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington's disease treated with tetrabenazine. *Mov Disord* 2005;20(9):1244.

49. Parkinson Study Group, Huntington Study Group and Movement Disorders Society. Nineteenth Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2005;20(9):1235-1249.
50. Hyson C for the Huntington Study Group. Pre-2CARE: a dosage ranging trial of coenzyme Q10 in Huntington's Disease and in healthy subjects. Hereditary Diseases Foundation Annual Symposium, August 2004.
51. Hyson HC & the Huntington Study Group, QuBE: A bioequivalence study of coenzyme Q10 in healthy subjects. Movement Disorders Society Meeting. 2005.
52. Marshall FJ, Eberly S, Frank S, Oakes D and the Huntington Study Group/TETRA-HD Investigators. Predictors of response to tetrabenazine in Huntington's disease. *Mov Disord* 2006;21(9):1547.
53. Huntington Study Group PHAROS Investigators (Shinaman A, presenter). Willingness to consent for future use of DNA collected in the Prospective Huntington At Risk Observational Study (PHAROS). *Mov Disord* 2006;21(9):1555-1556.
54. Frank SA on behalf of the Huntington Study Group TETRA-HD Investigators. An open label study of tetrabenazine as anti-chorea therapy in Huntington disease. *Neuro* 2007;68(Suppl 1):A365.
55. Marder K and the Huntington Study Group PHAROS Investigators. Cross-sectional assessment of diet in individuals at risk for Huntington's disease (PHAROS). *Neuro* 2007;68(Suppl 1):A230.
56. Paulsen JS, Langbehn DR, Wang C, Duff K, Beglinger LJ, Carlozzi NE, Queller S, Stout JC, and the PREDICT-HD Investigators of the Huntington Study Group. Cognitive Predictors of HD Diagnosis in PREDICT-HD: A Prospective Study of Cognition in Phenoconversion. Published in the program booklet of World Congress on Huntington's Disease 2007, Plenary Session III: S09.
57. Stout JC, Carlozzi NE, Queller S, Whitlock KB, Langbehn DR, Duff K, Beglinger LJ, Ross CA, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Longitudinal Assessment of Pre-HD from the PREDICT-HD COHORT: Preparation for Clinical Trails. A Prospective Study of Cognition in Phenoconversion. Published in the program booklet of World Congress on Huntington's Disease 2007, Plenary Session III: S10.
58. Biglan KM, Dorsey ER, Kieburtz K, Ross CA, Hersch S, Shoulson I, Matson W, and the Pre2CARE Investigators of the Huntington Study Group. Serum 8OHdG Levels in Manifest Huntington's Disease and Healthy Controls Treated with Coenzyme Q10. Published in the program booklet of World Congress on Huntington's Disease 2007, Plenary Session III: S16.

59. Duff K, Paulsen JS, Beglinger LJ, Stout JC, Carlozzi NE, Queller S, Langbehn DR, Wang C, and the PREDICT-HD Investigators of the Huntington Study Group. Predicting Depression in Pre-HD. Published in the program booklet of World Congress on Huntington's Disease 2007, Clinical Session I: S28.
60. Beglinger LJ, Paulsen JS, Duff K, Wang C, Langbehn DR, Watson D, Stout JC, Carlozzi NE, Queller S, and the PREDICT-HD Investigators of the Huntington Study Group. Obsessive and Compulsive Symptoms in Pre-Diagnosed Huntington's Disease. Published in the program booklet of World Congress on Huntington's Disease 2007, Clinical Session I: S29.
61. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Published in the program booklet of World Congress on Huntington's Disease 2007, Clinical Session III: S40.
62. Langbehn DR, Paulsen JS, and the PREDICT-HD investigators of the Huntington Study Group. Prospective Validation of CAG-Based Age of Diagnosis in Huntington's Disease. Published in the program booklet of World Congress on Huntington's Disease 2007, Clinical Session III: S46.
63. Dorsey ER on behalf of the Huntington Study Group TREND-HD Investigators. A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease – Preliminary Results. Published in the program booklet of World Congress on Huntington's Disease 2007, Clinical Session IV: S79.
64. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Factors Associated with the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington's Disease. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P52.
65. Langbehn DR, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Prospective Validation of CAG-Based Age of Diagnosis in Huntington's Disease. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P62.
66. Stout JC, Carlozzi NE, Queller S, Whitlock KB, Langbehn DR, Duff K, Beglinger LJ, Ross CA, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Longitudinal Assessment of Pre-HD From the PREDICT-HD COHORT: Preparation for Clinical Trials. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P63.

67. Paulsen JS, Langbehn DR, Wang C, Duff K, Beglinger LJ, Carlozzi NE, Queller S, Stout JC, and the PREDICT-HD Investigators of the Huntington Study Group. Cognitive Predictors of HD Diagnosis in PREDICT-HD: A Prospective Study of Cognition in Phenoconversion. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P86.
68. Carlozzi NE, Stout JC, Queller S, Whitlock KB, Langbehn DR, Beglinger LJ, Duff K, Ross CA, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Cross-Sectional Neurocognitive Measurement of Pre-HD Individuals in PREDICT-HD. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P87.
69. Duff K, Paulsen JS, Beglinger LJ, Stout JC, Carlozzi NE, Queller S, Langbehn DR, Wang C, and the PREDICT-HD Investigators of the Huntington Study Group. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P106.
70. Beglinger LJ, Paulsen JS, Duff K, Wang C, Langbehn DR, Watson D, Stout JC, Carlozzi NE, Queller S, and the PREDICT-HD Investigators of the Huntington Study Group. Obsessive and Compulsive Symptoms in Pre-Diagnosed Huntington's Disease. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P108.
71. Biglan KM, Dorsey ER, Kieburtz K, Ross CA, Hersch S, Shoulson I, Matson W, and the Pre2CARE Investigators of the Huntington Study Group. Serum 80HdG Levels in Manifest Huntington's Disease and Healthy Controls Treated with Coenzyme Q10. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P148.
72. Dorsey ER on behalf of the Huntington Study Group TREND-HD Investigators. A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington's Disease – Preliminary Results. Published in the program booklet of World Congress on Huntington's Disease 2007, Abstract P150.
73. Biglan KM, Ross CA, Langbehn DR, Aylward E, Stout JC, Queller S, Carlozzi N, Duff K, Beglinger LJ, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Subtle Motor Abnormalities in Pre-Manifest HD Are Associated with Gene Status, Probability of Disease Onset, and Striatal Atrophy. *Neurotherapeutics* 2008; 5(2):362.
74. Hersch S for the Huntington Study Group PHEND Investigators. PHEND-HD: A Safety, Tolerability, and Biomarker Study of Phenylbutyrate in Symptomatic HD. *Neurotherapeutics* 2008; 5(2):363.
75. Dorsey ER for the Huntington Study Group TREND-HD Investigators. A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of

- Huntington Disease – 12-Month Results. *Neurotherapeutics* 2008; 5(2):363.
76. Chirieac MC, Shinaman A, Shoulson I, and the Huntington Study Group COHORT Investigators. COHORT: A Snapshot of Baseline Characteristics. *Neurotherapeutics* 2008; 5(2):365.
 77. Kayson EP and the Huntington Study Group PHAROS Investigators. Five Years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study). *Neurotherapeutics* 2008; 5(2):366.
 78. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Influence of Insurance on the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington Disease. *Neurotherapeutics* 2008; 5(2):368.
 79. Quaid K, Sims S, Swenson M, Harrison J, Moskowitz C, Stepanov N, Suter G, Westphal B, and the Huntington Study Group PHAROS Investigators. Living at Risk: Concealing Risk and Preserving Hope in Huntington Disease. *Neurotherapeutics* 2008; 5(2):368-369.
 80. Johnson SA, Stout JC, Queller S, Whitlock K, Langbehn D, Aylward E, Paulsen J, and the PREDICT-HD Investigators of the Huntington Study Group. Longitudinal Decline in Negative Emotion Recognition Prior to Diagnosis in Huntington's Disease. *Neurotherapeutics* 2008; 5(2):369.
 81. Nopoulos P, Paulsen J, Beglinger L, Johnson H, Magnotta V, Pierson R, Langbehn D, and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Abnormal Structure of Cerebral White and Cortical Gray Matter in Preclinical Huntington's Disease. *Neurotherapeutics* 2008; 5(2):369-370.
 82. Whitlock KB, Stout JC, Queller S, Langbehn DR, Carlozzi NE, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Item Reduction of the University of Pennsylvania Smell ID Test: Preparation for Clinical Trials in pre-HD using the Predict HD Cohort. *Neurotherapeutics* 2008; 5(2):372.
 83. Stout JC, Carlozzi NE, Queller S, Whitlock KB, Johnson SA, Langbehn DR, Beglinger LJ, Duff K, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Candidates for Neurocognitive Markers in PRE-HD: Longitudinal Assessment from the PREDICT-HD COHORT. *Neurotherapeutics* 2008; 5(2):372.
 84. Stout JC, Queller S, Whitlock KB, Carlozzi NE, Langbehn DR, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Controlling for Individual Differences in Neurocognitive Markers in Pre-Diagnosed HD in the Predict-HD Cohort. *Neurotherapeutics* 2008; 5(2):373.

85. Dorsey ER, Beck C, Adams M, Chadwick G, de Blicke EA, McCallum C, Deuel L, Clarke A, Stewart R, Shoulson I, and the Huntington Study Group TREND-HD Investigators. Communicating Findings to Research Participants: Preliminary Results from the TREND-HD Study. *Neurotherapeutics* 2008; 5(2):374-375.
86. Biglan K, Zhao H, Oakes D, Kayson E, and Shoulson I. Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington's Disease. *Annals of Neurology*; 64(12): S51.
87. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, and Jankovic J. A Study of Chorea After Tetrabenazine Withdrawal in Patients with Huntington Disease. *Clinical Neuropharmacology*; 31(3): 127-133.
88. E. Ray Dorsey, MD, MBA; Christopher A. Beck, PhD; Mary Adams, MTS; Gary Chadwick, PharmD, MPH; Elisabeth A. de Blicke, MPA, CCRC; Colleen McCallum, MSW; Leslie Briner; Lisa Deuel, BA; Anthony Clarke, PhD; Rick Stewart, BS; Ira Shoulson, MD; and the Huntington Study Group TREND-HD Investigators. Communicating Clinical Trial Results to Research Participants. *Arch Neurol.* 2008; 65(12): 1590-1595.
89. The TREND-HD Investigators of the Huntington Study Group. Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. *Arch Neurol.* 2008; 65(12):1582-1589.
90. Aylward E, Nopoulos P, Johnson H, Juhl A, Magnotta V, Pierson R, Langbehn D, Ross C, Paulsen J, and the PREDICT-HD Investigators of the Huntington Study Group. Longitudinal Structural MRI Data from PREDICT-HD: Striatal and Cortical Changes in Pre-Clinical HD. *Neurotherapeutics* 2009; 6:202-3.
91. The Huntington Study Group (Kiebertz K, primary author). Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND). *Neurotherapeutics* 2009; 6:203.
92. Evans K, Anderson K, Borowsky B, Duff K, Giuliano J, Guttman M, Ho A, Langbehn D, Paulsen J, Sills T, Vaccarino A, van Kammen, D and the FuRST-pHD and PREDICT-HD Investigators and Coordinators of the Huntington Study Group. The Functional Rating Scale Taskforce for Pre-Huntington's Disease: An Empirically-Driven Initiative for New Scale Development. *Neurotherapeutics* 2009; 6:205.
93. Vaccarino A, Anderson K, Borowsky B, Duff K, Evans K, Giuliano J, Guttman M, Ho A, Langbehn D, Paulsen J, Sills T, van Kammen, D and the FuRST-pHD and PREDICT-HD Investigators and Coordinators of the Huntington Study Group. An Item Response Analysis of Depressive

- Symptomology in Pre-Huntington Disease. *Neurotherapeutics* 2009; 6:205.
94. Block RC, Dorsey ER, Beck CA, and Shoulson I for the Huntington Study Group TREND-HD Investigators. Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease. *Neurotherapeutics* 2009; 6:205-6.
 95. Duff K, Beglinger LJ, Stout JC, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Predicting Cognitive Decline: Another Method for Stratifying Samples? *Neurotherapeutics* 2009; 6:208-9.
 96. Oster E, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K and Dorsey ER for the Huntington Study Group PHAROS Investigators. Insurance Ownership and Genetic Risk. *Neurotherapeutics* 2009; 6:210-11.
 97. Huntington Study Group COHORT Investigators (Nicholl S, primary author). Cooperative Huntington Observational Research Trial (COHORT): Baseline Mental Health Risks. *Neurotherapeutics* 2009; 6:211.
 98. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K for the Huntington Study Group. Fear of health insurance loss among individuals at risk for Huntington disease. *The Amer Journal of Med Genetics* 2008; 146A:2070-77.
 99. Cudkowicz ME, McDermott M, Doolan R, Marshall F, Kieburtz K, HSG. A Phase 2 Trial of Minocycline in Huntington's Disease. *Movement Disorders* 2009; 24(1): S164.
 100. Paulsen J, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams J, Simpson S, Langbehn D, van Kammen D, the PREDICT-HD Investigators of the Huntington Study Group. Challenges Assessing Functional Outcomes in Early Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 36.
 101. Rowe KC, Langbehn DR, Duff K, Beglinger LJ, Wang C, Moser DJ, O'Rourke JF, Stout JC, Paulsen JS and the Predict-HD Investigators of the Huntington Study Group. Self-Paced Timing Task Detects Subtle Changes in Pre-Diagnosed Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 48.
 102. Vaccarino A, Evans K, Gilbert-Evans S, Sills T, Anderson K, Borowsky B, Duff K, Giuliano J, Guttman M, Ho A, Langbehn D, Paulsen J, van Kammen D and the FuRST-pHD and PREDICT-HD Investigators and Coordinators. Assessing Behavioural Symptoms Prior to Clinical Diagnosis of Huntington's Disease: The Functional Rating Taskforce for Pre-Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 50.

103. Aylward EH, Nopoulos PC, Pierson RK, Langbehn DR, Ross CA, Juhl AR, Johnson HJ, Magnotta VA, Paulsen JS and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Longitudinal Change in Striatal Volume in Prodromal Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 51.
104. Nopoulos P, Johnson H, Magnotta V, Pierson R, Langbehn D, Ross C, Aylward E, Paulsen J and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Global and Regional Brain Morphology in Huntington's Disease Prior to Diagnosis. *Clinical Genetics* 2009; 76(Suppl. 1): 52.
105. Nopoulos PC, Johnson HJ, Magnotta VA, Pierson RK, Langbehn DR, Ross CA, Aylward EA, Paulsen JS and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Cerebral Complex Morphology in Subjects with Huntington's Disease Prior to Diagnosis. *Clinical Genetics* 2009; 76(Suppl. 1): 52.
106. Duff K, Paulsen JS, Wang C, Mills JA, Beglinger LJ, Langbehn D and the Predict-HD Investigators. Stress and Coping in Pre-Diagnosed Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 53.
107. Constantinescu R, Rosengren L, Broucht A, Romer M, Kiebertz DOK and the Huntington Study Group INTRO-HD Investigators. Levels of Tau Protein in the Cerebrospinal Fluid in Huntington's Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 54.
108. Evans K, Vaccarino A, Sills T, Gilbert-Evans S, Anderson K, Borowsky B, Duff K, Giuliano J, Guttman M, Ho A, Landwehrmeyer GB, Langbehn D, Paulsen J, van Kammen D and the FuRST-pHD, PREDICT-HD and REGISTRY Investigators and Coordinators. Assessing Depression in Huntington Disease: Relationship Between Disease Progression, Depression and Manifestation of Motor Symptoms. *Clinical Genetics* 2009; 76(Suppl. 1): 66.
109. Erwin C, Williams JK, Juhl AR, Mengling M, Mills JA, Bombard Y, Hayden MR, Kayson E, Shoulson I, Quaid K, Taylor S, Paulsen JS and the Investigators of the Huntington Study Group. The RESPOND-HD Study of Genetic Discrimination in Persons At Risk for Huntington Disease. *Clinical Genetics* 2009; 76(Suppl. 1): 97.
110. Oster E, Quaid K, Shoulson I, Dorsey ER for the Huntington Study Group PHAROS Investigators. Genetic Adverse Selection in Long-Term Care Insurance. *Clinical Genetics* 2009; 76(Suppl. 1): 97.
111. Williams JK, Erwin C, Juhl AR, Mengling M, Bombard Y, Hayden MR, Shoulson I, Taylor S, Paulsen JS and the Investigators of the Huntington Study Group. The RESPOND-HD Study of Genetic Discrimination and Stigma Experiences of People At Risk for HD. *Clinical Genetics* 2009; 76(Suppl. 1): 101.

112. Langbehn DR, Hayden M, Paulsen JS and the PREDICT-HD Investigators of the Huntington Study Group. CAG-Repeat Length and the Age of Onset in Huntington Disease (HD): A Review and Validation Study of Statistical Approaches. *Clinical Genetics* 2009; 76(Suppl. 1): 107.
113. Aylward EH, Ross CA, Nopoulos PC, Pierson RK, Mills JA, Langbehn DR, Johnson HJ, Magnotta VA, Paulsen JS, the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Striatal Volume Distinguishes Incident Cases of HD from Nonconverter Prodromal Cases: Findings from PREDICT-HD. *Clinical Genetics* 2009; 76(Suppl. 1): 115.
114. Oster E, Juhl AR, Erwin C, Williams JK, Mengling M, Mills JA, Bombard Y, Hayden MR, Shoulson I, Taylor S, Dorsey ER, Paulsen JS, and the Huntington Study Group PREDICT-HD and PHAROS Investigators. Genetic Discrimination in Insurance: Attitudes, Behaviors and Experiences. *Clinical Genetics* 2009; 76(Suppl. 1): 115.
115. Langbehn D, Paulsen J, and the PREDICT-HD Investigators of the Huntington Study Group. Multivariate Clinical Predictors of Huntington Disease (HD): Prospective Results from the PREDICT-HD Study. *Neurotherapeutics* 2010; 7(1):137.
116. Goh A, Yastrubetskaya O, and Chiu E. Genetic Discrimination of Individuals at Risk of Huntington's Disease: Further Analysis of the RESPOND-HD Data From Australia (Site 144). *Neurotherapeutics* 2010; 7(1):138.
117. Aylward E, Nopoulos P, Ross C, Pierson R, Mills J, Langbehn D, Magnotta V, Johnson H, Paulsen J, and the PREDICT-HD Investigators of the Huntington Study Group. Striatal Volume Distinguishes Converters from Non-Converters: Findings from PREDICT-HD. *Neurotherapeutics* 2010; 7(1):141.
118. Richardson K, McCusker E, Loy C, Griffith J, Mills J, Paulsen J, and the PREDICT-HD Investigators of the Huntington Study Group. Lack of Awareness of Motor and Cognitive Phenocconversion in Huntington's Disease. *Neurotherapeutics* 2010; 7(1):144.
119. Waters S, Tedroff J, and Kieburtz K. Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score. *Neurotherapeutics* 2010; 7(1):144.
120. Tedroff, Lindskov Krogh P, Buusman A, and Rembratt A. Pridopidine (ACR16) in Huntington's Disease: An Update on the MermaiHD and HART Studies. *Neurotherapeutics* 2010; 7(1):144-145.
121. Erwin C, Williams J, Juhl A, Paulsen J, and the Investigators of the Huntington Study Group. Worry and Experience of Genetic Discrimination in Persons at Risk for Huntington Disease. *Neurotherapeutics* 2010; 7(1):146.

122. Huntington Study Group PHAROS Investigators. Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington's Disease by Gene Status: The Prospective Huntington's Disease Observational At-Risk Study (PHAROS). *Neurotherapeutics* 2010; 7(1):146.

Reports, Releases, and Position Papers

1. Huntington Study Group To Plan and Carry Out Clinical Trials (November 15, 1993).
2. Huntington Study Group Ethical and Conflict-of-Interest Guidelines (June, 1994).
3. The Huntington Study Group Moves Forward to Plan and Conduct Clinical Research Trials (August, 1994).
4. HSG Progress Report, 1993-94 (December, 1994).
5. HSG Policy on Non-Disclosure of CAG Trinucleotide Repeat Length (CAGn) Genetic (DNA) Information (February 10, 1995).
6. HSG Accomplishments and Goals, 1995-1996, 1996-1997, 1997-1998, 1998-1999.
7. Constitution and Bylaws of the HSG (September 13, 1996).
8. HSG Position Statement On Experimental Surgical Treatments In HD (January 10, 1997) K. Kiebertz, K. Shannon for the Surgical Approaches Working Group and the HSG Executive Committee.
9. HSG Policy for Storage and Use of Biological Human Research Samples (April 24, 2001).
10. HSG Policy Statement on Publication and Conflict of Interest Pertaining to Clinical Research Involving Persons with Huntington's Disease (HD) (October 24, 2002).

In Press

1. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, and the Predict-HD Investigators and Coordinators of the Huntington Study Group. Detection of brain disease decades before diagnosis: the Predict HD study. *Neurology*.
2. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Janavic. A study of chorea after tetrabenazine withdrawal in patients with Huntington's disease. *Clinical Neuropharmacology*.

Reports Supported by The Huntington Study Group

1. Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LS, Lindsey R, Hersch SM, Jope RS, Albin RL, Detloff PJ. Ectopically expressed CAG repeats cause intranuclear

inclusions and a progressive late onset neurological phenotype in the mouse. *Cell* 1997; 91:753-763.